BCDA BioCardia Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BCDA

Price (delayed)

$1.89

Market cap

$38.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$34.91M

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and respiratory disease. CardiAMP autologous and Neurokinin-1 Receptor Positive allogenic cell therapies are the Company's ...

Highlights
BioCardia's gross profit has increased by 32% YoY
BioCardia's revenue has increased by 32% YoY
The equity has dropped by 74% year-on-year and by 61% since the previous quarter
BCDA's quick ratio has plunged by 52% YoY and by 41% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biocardia.com
Peers: OVID

Key stats

What are the main financial stats of BCDA
Market
Shares outstanding
20.22M
Market cap
$38.21M
Enterprise value
$34.91M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
20.08
Price to sales (P/S)
28.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.75
Earnings
Revenue
$1.36M
EBIT
-$12.08M
EBITDA
-$11.69M
Free cash flow
-$10.26M
Per share
EPS
-$0.64
Free cash flow per share
-$0.51
Book value per share
$0.09
Revenue per share
$0.07
TBVPS
$0.35
Balance sheet
Total assets
$7.13M
Total liabilities
$5.23M
Debt
$1.56M
Equity
$1.9M
Working capital
$1.29M
Liquidity
Debt to equity
0.82
Current ratio
1.32
Quick ratio
1.25
Net debt/EBITDA
0.28
Margins
EBITDA margin
-862.2%
Gross margin
100%
Net margin
-891.1%
Operating margin
-891.2%
Efficiency
Return on assets
-129.3%
Return on equity
-274.3%
Return on invested capital
-2,196.9%
Return on capital employed
-386.3%
Return on sales
-891.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCDA stock price

How has the BioCardia stock price performed over time
Intraday
5%
1 week
1.61%
1 month
-6.9%
1 year
15.24%
YTD
-9.57%
QTD
-3.08%

Financial performance

How have BioCardia's revenue and profit performed over time
Revenue
$1.36M
Gross profit
$1.36M
Operating income
-$12.08M
Net income
-$12.08M
Gross margin
100%
Net margin
-891.1%
BioCardia's gross profit has increased by 32% YoY
BioCardia's revenue has increased by 32% YoY
The net margin has increased by 29% year-on-year
BioCardia's operating margin has increased by 29% YoY

Growth

What is BioCardia's growth rate over time

Valuation

What is BioCardia stock price valuation
P/E
N/A
P/B
20.08
P/S
28.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.75
The EPS has grown by 16% YoY and by 4.5% from the previous quarter
BCDA's P/B is 99% above its last 4 quarters average of 10.1 and 75% above its 5-year quarterly average of 11.5
The equity has dropped by 74% year-on-year and by 61% since the previous quarter
BCDA's P/S is 72% below its 5-year quarterly average of 100.8 but 18% above its last 4 quarters average of 23.9
BioCardia's revenue has increased by 32% YoY

Efficiency

How efficient is BioCardia business performance
The company's return on equity has shrunk by 147% YoY and by 33% QoQ
The ROA has plunged by 65% YoY and by 17% from the previous quarter
BioCardia's ROIC has decreased by 48% from the previous quarter
The ROS has grown by 29% YoY

Dividends

What is BCDA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCDA.

Financial health

How did BioCardia financials performed over time
BCDA's total assets is 36% higher than its total liabilities
BCDA's quick ratio has plunged by 52% YoY and by 41% from the previous quarter
BCDA's current ratio has shrunk by 51% YoY and by 40% QoQ
The debt is 18% smaller than the equity
BioCardia's debt to equity has soared by 148% from the previous quarter
The equity has dropped by 74% year-on-year and by 61% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.